ID   NPC-TW03
AC   CVCL_6010
SY   NPC-TW 03; TW 03; TW-03; TW03; EBV (-) TW03
DR   BTO; BTO_0006139
DR   Wikidata; Q54930974
RX   PubMed=7685844;
RX   PubMed=10744066;
CC   Population: Chinese.
CC   Virology: EBV-negative, but was originally EBV-positive.
CC   Doubling time: ~13-14 hours (PubMed=10744066).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Derived from site: In situ; Pharynx, nasopharynx; UBERON=UBERON_0001728.
DI   NCIt; C3871; Nasopharyngeal carcinoma
DI   ORDO; Orphanet_150; Nasopharyngeal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   36Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 16
//
RX   PubMed=7685844;
RA   Lin C.-T., Chan W.-Y., Chen W., Huang H.-M., Wu H.-C., Hsu M.-M.,
RA   Chuang S.-M., Wang C.-C.;
RT   "Characterization of seven newly established nasopharyngeal carcinoma
RT   cell lines.";
RL   Lab. Invest. 68:716-727(1993).
//
RX   PubMed=10744066; DOI=10.1038/labinvest.3780035;
RA   Teramoto N., Maeda A., Kobayashi K., Hayashi K., Oka T., Takahashi K.,
RA   Takada K., Klein G., Akagi T.;
RT   "Epstein-Barr virus infection to Epstein-Barr virus-negative
RT   nasopharyngeal carcinoma cell line TW03 enhances its tumorigenicity.";
RL   Lab. Invest. 80:303-312(2000).
//